GLP-1 Drugs Are Being Dosed All Wrong
Notas do episódio
FULL EPISODE: https://youtu.be/0ilcJJx_AxI?si=c3p-fnR5bRgIXjgn
Jay Campbell is the author of *Metabolic Awakening with GLP Peptides* and a prominent voice on GLP peptides and GLP1 drugs, arguing that these compounds have been around for years but only gained mainstream attention with semaglutide/Wegovy around 2020. He views them as powerful tools for weight loss and metabolic health, but says their real value depends on smart, context-driven use rather than the aggressive dosing often seen in pharmaceutical settings. Campbell believes newer agents like Mounjaro/Zepbound and retatrutide may offer even broader benefits, including improved insulin signaling, nutrient partitioning, fat loss, and possibly effects on compulsive behaviors. At the same time, he cautions that these drugs are not magic bullets and that side effects, rebound issues, and muscle loss can be minimized when they are used more carefully and strategically.
(00:00:00) Semaglutide’s Appetite-Suppressing Rise and Tiny Doses
(00:03:25) Wegovy’s Crude Appetite Suppression and Nausea
(00:06:18) Microdosed peptides, not receptor-overwhelming pharmaceutical doses
(00:10:44) Hormone Panel Tactics Return for Peptides
Full show notes (including all links mentioned): https://jjvirgin.com/drjay